Chondrial Therapeutics, Inc. is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. We are dedicated to the pursuit of scientific research leading to the treatment for Friedreich’s Ataxia and other mitochondrial diseases.
Mission: To discover and develop orphan drugs that target and treat rare debilitating mitochondrial diseases, such as Friedreich’s Ataxia.
Approach: To utilize our proprietary protein replacement platform to initially target Friedreich’s Ataxia and then other rare mitochondrial diseases.
Goal: To reduce symptoms in individuals with mitochondrial diseases.
This organization is headquartered in Bala Cynwyd, Pennsylvania.
In The News
- Rare Diseases In Crosshairs Of A New Philadelphia Startup, CBS-3, April 11, 2017.